
Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
Tolvaptan (Jynarque )is a selective vasopressin V2-receptor antagonist .
Indication: Tolvaptan (Jynarque )is a selective vasopressin V2-receptor antagonist indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease. It is also used to treat hyponatremia in patients with heart failure or syndrome of inappropriate antidiuretic hormone.
Insight:
Source:





